A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema
…, JJ Zwaginga, H Roelofs, WE Fibbe… - … Journal of Medicine, 2016 - academic.oup.com
Background: Mesenchymal stromal cells (MSCs) may reduce inflammation and promote tissue
repair in pulmonary emphysema. Aim: To study the safety and feasibility of bone marrow-…
repair in pulmonary emphysema. Aim: To study the safety and feasibility of bone marrow-…
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple …
…, PW Wijermans, WE Fibbe… - Blood, The Journal …, 2003 - ashpublications.org
We compared the efficacy of intensified chemotherapy followed by myeloablative therapy
and autologous stem cell rescue with intensified chemotherapy alone in patients newly …
and autologous stem cell rescue with intensified chemotherapy alone in patients newly …
[HTML][HTML] Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study
…, ML Zandvliet, VAL Huurman, WE Fibbe… - Journal of translational …, 2015 - Springer
Background Mesenchymal stromal cells (MSC) may serve as an attractive therapy in renal
transplantation due to their immunosuppressive and reparative properties. While most studies …
transplantation due to their immunosuppressive and reparative properties. While most studies …
Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first‐line treatment in untreated multiple myeloma
…, AJ Croockewit, AW Dekker, WE Fibbe… - British journal of …, 1999 - Wiley Online Library
We examined the feasibility of achieving a rapid response in patients with previously untreated
multiple myeloma by administering vincristine 0.4 mg and doxorubicin 9 mg/m 2 as a …
multiple myeloma by administering vincristine 0.4 mg and doxorubicin 9 mg/m 2 as a …
SERUM TRANSFORMING GROWTH FACTOR-β1 LEVELS IN BONE MARROW TRANSPLANT RECIPIENTS CORRELATE WITH BLOOD CELL COUNTS AND …
…, WE Fibbe, HC van Houwelingen, E Goulmy - …, 1999 - journals.lww.com
Objective. Profound immunosuppression and extensive fibrotic changes in the skin are
characteristic for graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (…
characteristic for graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (…
Differential immunomodulatory effects of fetal versus maternal multipotent stromal cells
…, E van Beelen, GMJS de Groot-Swings, WE Fibbe… - Human immunology, 2009 - Elsevier
Protective mechanisms are likely to be present at the fetomaternal interface because fetus-specific
alloreactive T cells present in the decidua do not harm the fetus. We tested the …
alloreactive T cells present in the decidua do not harm the fetus. We tested the …
[HTML][HTML] Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal …
…, C Van Kooten, FHJ Claas, WE Fibbe… - Journal of translational …, 2014 - Springer
Background Kidney transplantation has improved survival and quality of life for patients with
end-stage renal disease. Despite excellent short-term results due to better and more potent …
end-stage renal disease. Despite excellent short-term results due to better and more potent …
Factors influencing the incidence of infections in Felty's syndrome
FC Breedveld, WE Fibbe, J Hermans… - Archives of internal …, 1987 - jamanetwork.com
• To identify clinical and laboratory risk factors for the susceptibility to infections in Felty's
syndrome, 46 patients were studied prospectively during a total number of 431 periods of three …
syndrome, 46 patients were studied prospectively during a total number of 431 periods of three …
Second‐line treatment for acute graft‐versus‐host disease with mesenchymal stromal cells: A decision model
…, M Algeri, F Locatelli, WE Fibbe… - European Journal of …, 2018 - Wiley Online Library
Objective No standard second‐line treatment exists for acute graft‐versus‐host disease
steroid‐refractory (SR‐aGvHD), and long‐term outcomes remain poor. Mesenchymal stromal …
steroid‐refractory (SR‐aGvHD), and long‐term outcomes remain poor. Mesenchymal stromal …
Impaired effector memory T-cell regulation facilitates graft versus host disease in CCR7-deficient bone marrow transplant chimeras
…, TJC van Berkel, M Lipp, JJ Zwaginga, WE Fibbe… - …, 2009 - journals.lww.com
… Lipp: contributed new reagents or analytic tools; JJ Zwaginga: participated in research
design and in the writing of the manuscript; WE Fibbe: participated in research design and in the …
design and in the writing of the manuscript; WE Fibbe: participated in research design and in the …